epi-7386
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2020 (NCT04421222)
Timeline
Indications
Studied for
Mechanism of action
- Androgen ReceptorINHIBITOR
AR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06312670 | Phase 2 | May 16, 2024 | Case Western Reserve University, University of Rochester |
| NCT05295927 | Phase 1 | Mar 23, 2022 | — |
| NCT05075577 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2021 | ESSA Pharmaceuticals |
| NCT04421222 | Phase 1 | Jun 30, 2020 | ESSA Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ESSA Pharmaceuticals | For profit | 2 | 2 | 2 | 2020 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1